3649 results for «799»
3649 results
Insight from new evidence for complex PCI: value of imaging (CHIP IVUS) and left ventricular support (CHIP BCIS 3)
21 May 2026 – From EuroPCR 2026
This session reviews the impact of recent evidence on complex PCI, highlighting the value of intracoronary imaging (CHIP IVUS trial) and left ventricular assist devices (CHIP BCIS 3 trial). Through case discussions, participants reflect on how these innovations influence daily clinical practice and enhance procedural planning...
Left main interventions: pushing the boundaries
21 May 2026 – From EuroPCR 2026
Examine contemporary strategies for distal left main bifurcation disease treatment, including debates on complex bifurcation and high-risk PCI approaches. The session emphasizes the critical role of coronary imaging in guiding decision-making and showcases clinical cases illustrating management of left main interventions under challenging conditions.
Challenging procedures for bifurcation lesions
22 May 2026 – From EuroPCR 2026
Explore a series of challenging cases in coronary bifurcation interventions, highlighting complex decision-making scenarios, pharmaco-invasive strategies guided by IVUS, and tailored techniques for reintervention. Emphasis is placed on imaging-guided PCI and simplifying complex double bifurcation and long lesion treatments to optimize patient outcomes.
Beyond stent: use of DCB in CTO
22 May 2026 – From EuroPCR 2026
This session focuses on the innovative use of drug-coated balloons (DCB) in chronic total occlusion (CTO) interventions. It reviews combined plaque modification techniques, complex multivessel PCI cases involving CTOs, and strategy considerations such as hybrid therapy versus full metal jacket, emphasizing vessel biology preservation during revascularisation.
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Author

Author
Routine cerebral embolic protection in transcatheter aortic valve implantation: the British Heart Foundation (BHF) PROTECT-TAVI trial
29 Mar 2025
Aaysha Cader and Ali Nazmi Calik provide their take on the BHF PROTECT-TAVI trial, presented by Rajesh Kharbanda at ACC.25 in Chicago.

Author

Author
SMT’s Supraflex Cruz shows consistent and robust clinical outcomes across key global studies presented at TCT 2025
29 Oct 2025
Evidence base: current data on TAVI durability and long-term outcomes
22 Jul 2026
This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.

Author

Author